Physician profile

Denise Shaw

Obstetrics & Gynecology · Tulsa, OK

NPI 1760457246

$491.77

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$12.69

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lupin INC. $119.81 2019
Abbvie INC. $96.26 2019-2021
Therapeuticsmd, INC. $90.45 2019-2020
Exeltis, USA INC. $34.42 2020
Evofem Biosciences, INC. $28.66 2020-2021
Allergan, INC. $28.30 2019-2020
Merck Sharp & Dohme LLC $26.12 2019
Mission Pharmacal Company $18.44 2020
Baxter Healthcare $12.69 2023 Floseal
Covidien LP $12.62 2019
Mylan Pharmaceuticals INC. $12.49 2020
Acessa Health INC. $11.51 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Denise Shaw

$491.77

in general payments reported 2019-2025

Years
2019-2023
Top company
Lupin INC.

https://glasscript.com/doctor/34024/denise-shaw

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.